A Phase III, Multicentre, Open Label, Flexible Dose, Long Term Safety Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia [EXTENSION OF 700027662, 700242621, AND 700242623]
Latest Information Update: 10 Apr 2023
At a glance
- Drugs Colestilan (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Adverse reactions; Registrational
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 31 Mar 2014 New trial record
- 21 Sep 2010
- 08 Apr 2010